DNA, Peptide Vaccines Advance Against GBM.

DNA-based GNOS-PV01 and peptide-based NeoVax vaccines show promise for glioblastoma patients, with GNOS-PV01 effective against the challenging MGMT-unmethylated subtype.

• Why it matters: Glioblastoma has limited treatment options, especially for MGMT-unmethylated tumors, which have a poor prognosis. Developing effective personalized vaccines could improve outcomes for these patients.
• What they did: A Phase I trial tested two personalized vaccine strategies—DNA-based GNOS-PV01 and peptide-based NeoVax—in glioblastoma patients, highlighting their potential as promising approaches.
• The result: Findings suggest that GNOS-PV01 may be effective against MGMT-unmethylated glioblastoma, indicating these vaccines could offer targeted immunotherapy options for difficult-to-treat subtypes.